Adicet Bio Inc. (NASDAQ: ACET) announced preliminary data from its Phase 1 study of ADI-001, an investigational cell therapy for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE